Skip to content 
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. more
| Time Frame | BIO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -9.79% | 0.72% | -1.31% |
| 1-Month Return | -15.29% | 1.27% | 0.78% |
| 3-Month Return | -13.92% | 3.13% | 3.46% |
| 6-Month Return | -6.93% | 15.81% | 6.19% |
| 1-Year Return | -6.45% | 8.89% | 11.68% |
| 3-Year Return | -43.41% | 20.79% | 71.21% |
| 5-Year Return | -59.34% | 35.89% | 74.81% |
| 10-Year Return | 104.58% | 138.44% | 256.59% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 2.92B | 2.80B | 2.67B | 2.57B | 2.58B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.88,"profit":true},{"date":"2023-12-31","value":91.4,"profit":true},{"date":"2024-12-31","value":87.82,"profit":true},{"date":"2025-12-31","value":88.39,"profit":true}] |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.14,"profit":true},{"date":"2023-12-31","value":96.88,"profit":true},{"date":"2024-12-31","value":92.46,"profit":true},{"date":"2025-12-31","value":96.51,"profit":true}] |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.68,"profit":true},{"date":"2023-12-31","value":87.11,"profit":true},{"date":"2024-12-31","value":84.18,"profit":true},{"date":"2025-12-31","value":82.02,"profit":true}] |
| Gross Margin | 56.05% | 55.93% | 53.42% | 53.73% | 52.01% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.79,"profit":true},{"date":"2023-12-31","value":95.3,"profit":true},{"date":"2024-12-31","value":95.85,"profit":true},{"date":"2025-12-31","value":92.8,"profit":true}] |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.34,"profit":true},{"date":"2023-12-31","value":95.72,"profit":true},{"date":"2024-12-31","value":97.55,"profit":true},{"date":"2025-12-31","value":94.7,"profit":true}] |
| Operating Income | 500.34M | 482.62M | 337.80M | 269.00M | 270.50M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.46,"profit":true},{"date":"2023-12-31","value":67.51,"profit":true},{"date":"2024-12-31","value":53.76,"profit":true},{"date":"2025-12-31","value":54.06,"profit":true}] |
| Total Non-Operating Income/Expense | 4.95B | (5.17B) | (1.14B) | (2.58B) | 771.50M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-104.44,"profit":false},{"date":"2023-12-31","value":-23.05,"profit":false},{"date":"2024-12-31","value":-52.12,"profit":false},{"date":"2025-12-31","value":15.59,"profit":true}] |
| Pre-Tax Income | 5.45B | (4.70B) | (850.10M) | (2.34B) | 995.50M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-86.33,"profit":false},{"date":"2023-12-31","value":-15.6,"profit":false},{"date":"2024-12-31","value":-42.99,"profit":false},{"date":"2025-12-31","value":18.27,"profit":true}] |
| Income Taxes | 1.19B | (1.08B) | (212.78M) | (498.30M) | 235.60M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-90.12,"profit":false},{"date":"2023-12-31","value":-17.81,"profit":false},{"date":"2024-12-31","value":-41.71,"profit":false},{"date":"2025-12-31","value":19.72,"profit":true}] |
| Income After Taxes | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.90M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.27,"profit":false},{"date":"2023-12-31","value":-14.98,"profit":false},{"date":"2024-12-31","value":-43.35,"profit":false},{"date":"2025-12-31","value":17.86,"profit":true}] |
| Income From Continuous Operations | 4.25B | (3.63B) | (159.30M) | (1.84B) | 759.90M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.44,"profit":false},{"date":"2023-12-31","value":-3.75,"profit":false},{"date":"2024-12-31","value":-43.43,"profit":false},{"date":"2025-12-31","value":17.9,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.90M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.27,"profit":false},{"date":"2023-12-31","value":-14.98,"profit":false},{"date":"2024-12-31","value":-43.35,"profit":false},{"date":"2025-12-31","value":17.86,"profit":true}] |
| EPS (Diluted) | 15.67 | 14.23 | 11.77 | 10.31 | 9.92 | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.81,"profit":true},{"date":"2023-12-31","value":75.11,"profit":true},{"date":"2024-12-31","value":65.79,"profit":true},{"date":"2025-12-31","value":63.31,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BIO | |
|---|---|
| Cash Ratio | 2.98 |
| Current Ratio | 5.62 |
| Quick Ratio | 4.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BIO | |
|---|---|
| ROA (LTM) | 1.67% |
| ROE (LTM) | 10.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BIO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.70 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BIO | |
|---|---|
| Trailing PE | 9.52 |
| Forward PE | 26.88 |
| P/S (TTM) | 2.77 |
| P/B | 0.93 |
| Price/FCF | 60 |
| EV/R | 2.55 |
| EV/Ebitda | 5.44 |
| PEG | 1.19 |
Bio-Rad Laboratories Inc (BIO) share price today is $270.67
Yes, Indians can buy shares of Bio-Rad Laboratories Inc (BIO) on Vested. To buy
Yes, you can purchase fractional shares of Bio-Rad Laboratories Inc (BIO) via the Vested app. You can start investing in Bio-Rad Laboratories Inc (BIO) with a minimum investment of $1.
You can invest in shares of Bio-Rad Laboratories Inc (BIO) via Vested in three simple steps:
The 52-week high price of Bio-Rad Laboratories Inc (BIO) is $343.12. The 52-week low price of Bio-Rad Laboratories Inc (BIO) is $211.43.
The price-to-earnings (P/E) ratio of Bio-Rad Laboratories Inc (BIO) is 9.5162
The price-to-book (P/B) ratio of Bio-Rad Laboratories Inc (BIO) is 0.93
The dividend yield of Bio-Rad Laboratories Inc (BIO) is 0.00%
The market capitalization of Bio-Rad Laboratories Inc (BIO) is $7.15B
The stock symbol (or ticker) of Bio-Rad Laboratories Inc is BIO
Consider the share price of Bio-Rad Laboratories Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Bio-Rad Laboratories Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Bio-Rad Laboratories Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Bio-Rad Laboratories Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Bio-Rad Laboratories Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Bio-Rad Laboratories Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
